Browse by UCL people
Group by: Type | Date
Number of items: 7.
2018
Vargas, FA;
Furness, AJS;
Litchfield, K;
Joshi, K;
Rosenthal, R;
Ghorani, E;
Solomon, I;
... Quezada, SA; + view all
(2018)
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Cancer Cell
, 33
(4)
pp. 649-663.
10.1016/j.ccell.2018.02.010.
|
2017
Hartwig, T;
Montinaro, A;
von Karstedt, S;
Sevko, A;
Surinova, S;
Chakravarthy, A;
Taraborrelli, L;
... Walczak, H; + view all
(2017)
The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2.
Molecular Cell
, 65
(4)
pp. 730-742.
10.1016/j.molcel.2017.01.021.
|
Vargas, FA;
Furness, AJS;
Solomon, I;
Joshi, K;
Mekkaoui, L;
Lesko, MH;
Rota, EM;
... Quezada, SA; + view all
(2017)
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
Immunity
, 46
(4)
pp. 577-586.
10.1016/j.immuni.2017.03.013.
|
2016
Menger, L;
Sledzinska, A;
Bergerhoff, K;
Vargas, FA;
Smith, J;
Poirot, L;
Pule, M;
... Quezada, SA; + view all
(2016)
TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors.
Cancer Research
, 76
(8)
pp. 2087-2093.
10.1158/0008-5472.CAN-15-3352.
|
2014
Lemke, J;
von Karstedt, S;
Abd El Hay, M;
Conti, A;
Arce, F;
Montinaro, A;
Papenfuss, K;
... Walczak, H; + view all
(2014)
Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1.
Cell Death Differ
, 21
(3)
pp. 491-502.
10.1038/cdd.2013.179.
|
2011
Arce, F;
Breckpot, K;
Collins, M;
Escors, D;
(2011)
Targeting lentiviral vectors for cancer immunotherapy.
Curr Cancer Ther Rev
, 7
(4)
pp. 248-260.
10.2174/157339411797642605.
|
Karwacz, K;
Bricogne, C;
MacDonald, D;
Arce, F;
Bennett, CL;
Collins, M;
Escors, D;
(2011)
PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8(+) T cells.
EMBO Molecular Medicine
, 3
(10)
581 - 592.
10.1002/emmm.201100165.
|